WO2006032697A3 - Parvovirus - Google Patents

Parvovirus Download PDF

Info

Publication number
WO2006032697A3
WO2006032697A3 PCT/EP2005/054771 EP2005054771W WO2006032697A3 WO 2006032697 A3 WO2006032697 A3 WO 2006032697A3 EP 2005054771 W EP2005054771 W EP 2005054771W WO 2006032697 A3 WO2006032697 A3 WO 2006032697A3
Authority
WO
WIPO (PCT)
Prior art keywords
parvovirus
capsid protein
modified
modified vpl
vpl
Prior art date
Application number
PCT/EP2005/054771
Other languages
English (en)
Other versions
WO2006032697A2 (fr
Inventor
Susanne Modrow
Torsten Lowin
Markus Moebs
Michael Broeker
Original Assignee
Intercell Ag
Susanne Modrow
Torsten Lowin
Markus Moebs
Michael Broeker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag, Susanne Modrow, Torsten Lowin, Markus Moebs, Michael Broeker filed Critical Intercell Ag
Priority to PL05799042T priority Critical patent/PL1791858T3/pl
Priority to US11/575,951 priority patent/US9573979B2/en
Priority to EP05799042A priority patent/EP1791858B1/fr
Priority to AT05799042T priority patent/ATE465173T1/de
Priority to DE602005020815T priority patent/DE602005020815D1/de
Publication of WO2006032697A2 publication Critical patent/WO2006032697A2/fr
Publication of WO2006032697A3 publication Critical patent/WO2006032697A3/fr
Priority to US15/408,485 priority patent/US20170260239A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14211—Erythrovirus, e.g. B19 virus
    • C12N2750/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une protéine de capside VP1 modifiée du parvovirus B19 présentant une activité enzymatique du type phospholipase A2 réduite comparativement à la protéine de capside VP1 de type sauvage du parvovirus B19 comportant la séquence d'acides aminés de SeqID 1.
PCT/EP2005/054771 2004-09-24 2005-09-23 Parvovirus WO2006032697A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL05799042T PL1791858T3 (pl) 2004-09-24 2005-09-23 Zmodyfikowane białko kapsydowe VP1 z parwowirusa B19
US11/575,951 US9573979B2 (en) 2004-09-24 2005-09-23 Modified VP1-capsid protein of parvovirus B19
EP05799042A EP1791858B1 (fr) 2004-09-24 2005-09-23 Proteine de capside vp1 modifiee du parvovirus b19
AT05799042T ATE465173T1 (de) 2004-09-24 2005-09-23 Verändertes vp-1capsidprotein von parvovirus b19
DE602005020815T DE602005020815D1 (de) 2004-09-24 2005-09-23 Verändertes vp-1capsidprotein von parvovirus b19
US15/408,485 US20170260239A1 (en) 2004-09-24 2017-01-18 Modified vp1-capsid protein of parvovirus b19

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04450180.7 2004-09-24
EP04450180 2004-09-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/575,951 A-371-Of-International US9573979B2 (en) 2004-09-24 2005-09-23 Modified VP1-capsid protein of parvovirus B19
US15/408,485 Division US20170260239A1 (en) 2004-09-24 2017-01-18 Modified vp1-capsid protein of parvovirus b19

Publications (2)

Publication Number Publication Date
WO2006032697A2 WO2006032697A2 (fr) 2006-03-30
WO2006032697A3 true WO2006032697A3 (fr) 2006-05-18

Family

ID=35809798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/054771 WO2006032697A2 (fr) 2004-09-24 2005-09-23 Parvovirus

Country Status (9)

Country Link
US (2) US9573979B2 (fr)
EP (2) EP2149583B1 (fr)
AT (1) ATE465173T1 (fr)
CY (1) CY1110185T1 (fr)
DE (1) DE602005020815D1 (fr)
ES (2) ES2344739T3 (fr)
PL (1) PL1791858T3 (fr)
PT (1) PT1791858E (fr)
WO (1) WO2006032697A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090215879A1 (en) * 2008-02-26 2009-08-27 University Of North Carolina At Chapel Hill Methods and compositions for adeno-associated virus (aav) with hi loop mutations
WO2010093784A2 (fr) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci
JP2013529894A (ja) 2010-04-07 2013-07-25 ノバルティス アーゲー パルボウイルスｂ１９のウイルス様粒子を生成するための方法
EP2446898A1 (fr) * 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Utilisation de l'hormone de croissance pour améliorer la réponse immunitaire chez des patients immunodéprimés
WO2012055814A1 (fr) 2010-10-25 2012-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composé induisant une accumulation de lbpa pour inhiber la transmission intercellulaire du vih
EP3332802A1 (fr) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Compositions de combinaisons immunogènes et utilisations de celles-ci
EP2736921B1 (fr) * 2011-07-25 2018-06-27 GlaxoSmithKline Biologicals SA Compositions et procédés d'évaluation de l'immunogénicité fonctionnelle de vaccins contre un parvovirus
CN116333057A (zh) 2016-05-13 2023-06-27 4D分子治疗有限公司 腺相关病毒变体衣壳和其使用方法
KR20220070075A (ko) 2017-09-20 2022-05-27 4디 몰레큘러 테라퓨틱스 아이엔씨. 아데노-관련 바이러스 변이체 캡시드 및 그 용도
CN111770999A (zh) 2017-11-27 2020-10-13 4D分子治疗有限公司 腺相关病毒变体衣壳和用于抑制血管生成的应用
JP2022521025A (ja) 2019-02-25 2022-04-04 ノバルティス アーゲー Ｂｉｅｔｔｉクリスタリン網膜症を治療するための組成物及び方法
JP2022520875A (ja) 2019-02-25 2022-04-01 ノバルティス アーゲー Ｂｉｅｔｔｉクリスタリン網膜症を治療するための組成物及び方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030668A2 (fr) * 1998-11-24 2000-06-02 Tripep Ab Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire
WO2003006067A2 (fr) * 2001-07-10 2003-01-23 Deutsches Krebsforschungszentrum Compositions comprenant une variante de parvovirus vp1 et une proteine de parvovirus ns1 destinee a induire la cytolyse

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
EP1537877A3 (fr) 1996-10-11 2005-08-03 The Regents Of The University Of California Conjugués polynucléotides immunostimulateurs/molécule immunomodulatrice
EP1039935A4 (fr) 1997-02-28 2005-04-27 Univ Iowa Res Found UTILISATION D'ACIDES NUCLEIQUES CONTENANT DES DINUCLEOTIDES CpG NON METHYLES DANS LE TRAITEMENT DES TROUBLES ASSOCIES AUX LIPOPOLYSACCHARIDES
EP1005368B1 (fr) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Utilisation d'acides nucléiques contenat un dinucléotide CpG non-methylé combiné avec de l'aluminium en tant qu'adjuvants
CA2289741A1 (fr) 1997-05-19 1998-11-26 Merck & Co., Inc. Adjuvant oligonucleotidique
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
DE69935507T2 (de) 1998-04-03 2007-12-06 University Of Iowa Research Foundation Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
EP1077708A1 (fr) 1998-05-06 2001-02-28 University Of Iowa Research Foundation Methodes de prevention et de traitement des parasitoses et maladies associees a l'aide d'oligonucleotides cpg
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
CA2418854A1 (fr) 2000-08-17 2002-02-21 Jorg Fritz Vaccin comprenant au moins un antigene et un peptide antimicrobien a base de cathelicidine ou un derive de ce peptide
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000030668A2 (fr) * 1998-11-24 2000-06-02 Tripep Ab Utilisation de particules de capsides de parvovirus dans l'inhibition de la proliferation et de la migration cellulaire
WO2003006067A2 (fr) * 2001-07-10 2003-01-23 Deutsches Krebsforschungszentrum Compositions comprenant une variante de parvovirus vp1 et une proteine de parvovirus ns1 destinee a induire la cytolyse

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BALLOU W RIPLEY ET AL: "Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1.", THE JOURNAL OF INFECTIOUS DISEASES. 15 FEB 2003, vol. 187, no. 4, 15 February 2003 (2003-02-15), pages 675 - 678, XP009062414, ISSN: 0022-1899 *
DORSCH SIMONE ET AL: "The VP1 unique region of parvovirus B19 and its constituent phospholipase A2-like activity.", JOURNAL OF VIROLOGY. FEB 2002, vol. 76, no. 4, February 2002 (2002-02-01), pages 2014 - 2018, XP009062413, ISSN: 0022-538X *
GIROD ANNE ET AL: "The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity.", THE JOURNAL OF GENERAL VIROLOGY. MAY 2002, vol. 83, no. Pt 5, May 2002 (2002-05-01), pages 973 - 978, XP009062412, ISSN: 0022-1317 *
SHIELDS L E ET AL: "IN VITRO HEMATOPOIESIS IS INHIBITED IN HUMANS AND NON-HUMAN PRIMATES BY RECOMBINANT PARVO VIRUS CAPSID", AMERICAN JOURNAL OF OBSTETRICS & GYNECOLOGY, MOSBY, ST LOUIS, MO, US, vol. 182, no. 1 Part 2, January 2000 (2000-01-01), pages S18, XP000914833, ISSN: 0002-9378 *

Also Published As

Publication number Publication date
US20070286870A1 (en) 2007-12-13
CY1110185T1 (el) 2015-01-14
US9573979B2 (en) 2017-02-21
DE602005020815D1 (de) 2010-06-02
EP1791858B1 (fr) 2010-04-21
ATE465173T1 (de) 2010-05-15
WO2006032697A2 (fr) 2006-03-30
EP1791858A2 (fr) 2007-06-06
PL1791858T3 (pl) 2010-09-30
ES2556710T3 (es) 2016-01-19
EP2149583B1 (fr) 2015-10-28
PT1791858E (pt) 2010-07-26
ES2344739T3 (es) 2010-09-06
US20170260239A1 (en) 2017-09-14
EP2149583A1 (fr) 2010-02-03

Similar Documents

Publication Publication Date Title
WO2006032697A3 (fr) Parvovirus
WO2006018652A3 (fr) Peptide
WO2007076032A3 (fr) Compositions et procédés de production d'une composition
WO2005012347A3 (fr) Nouveaux derives de l'insuline
WO2003012105A3 (fr) Isoforme de facteur de croissance
WO2006087550A3 (fr) Peptides fixant les amyloides, produits analogues et applications de ces peptides
WO2004111216A3 (fr) Variantes genetiques de la phospholipase
WO2006017355A3 (fr) Variants d'aprotinine ameliores
EP1344827A3 (fr) Protéines antigel de basidiomycètes
WO2007093848A3 (fr) Nouveaux polypeptides purifiés issus de helicobacter pylori
WO2005039626A3 (fr) Procedes et compositions a utiliser pour le traitement des diabetes
WO2008047370A3 (fr) Compositions et méthodes permettant d'induire l'angiogenèse
WO2006096690A3 (fr) Compositions et procedes d'inhibition de la signalisation de proteine g
WO2007085728A3 (fr) Composition comprenant plusieurs toxines botuliques
WO2005000862A3 (fr) Reactifs et procedes pour former des liaisons disulfure et pour glycosyler des proteines
WO2010026219A3 (fr) Nouveaux facteurs de réponse à l’éthylène de la tomate et leurs utilisations
WO2005072766A3 (fr) Peptides se liant aux proteines hsp90
WO2006043060A3 (fr) Proteine contenant le domaine mam
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
WO2003082897A3 (fr) Fragments de peptides actifs synthetiques
WO2002062964A3 (fr) Variants d'amine oxydase ap1
WO2007073845A3 (fr) Nouveau polypeptide presentant une activite d'esterase, esterase recombinee et leur utilisation
WO2006044294A3 (fr) Analogues de la proteine humaine c
WO2006122650A3 (fr) Photoproteine isolee aqdecay et utilisation
WO2007144492A3 (fr) Peptides a activite anti-proliferative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005799042

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11575951

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005799042

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11575951

Country of ref document: US